Investigational New Drug CDMO Market size is expected to reach USD 6.8 billion by 2028

 Investigational New Drug CDMO Industry Overview

The global investigational new drug CDMO market size is expected to reach USD 6.8 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.9% from 2021 to 2028. This is largely due to the increased R&D investments, along with stringent regulations pertaining to IND.

Investigational New Drug CDMO Market Segmentation

Grand View Research has segmented the global investigational new drug CDMO market based on product, service, end user, and region:

Based on the Product Insights, the market is segmented into Small Molecule and Large Molecule

  • The small molecule segment held the largest share of 89.0% in 2020 and is likely to remain dominant over the forecast period. This is largely due to the increasing number of small molecules in development. Small molecules constitute more than 90% of the drugs currently in the market.
  • The large molecule segment is anticipated to register the fastest CAGR of 8.8% throughout the forecast period. This is largely due to pharmaceutical and biotech companies investing more in the discovery and development of large molecule therapeutic proteins due to their specificity, which allows for the targeting of previously difficult-to-address conditions in disease states, such as oncology, neurology, and metabolic disease.

Based on the Service Insights, the market is segmented into Contract Development and Contract Manufacturing

  • The contract development segment dominated the market with a revenue share of 85.5% in 2020. The segment is also projected to expand at the fastest CAGR during the forecast period. The contract development offers several benefits over in-house development of drugs, such as access to industry experts, less time to market, cost-effectiveness, and more focus on core competencies. 
  • The contract manufacturing segment is anticipated to witness lucrative growth over the forecast period. Sponsor firms developing the therapeutics are encountering extreme pressure to control costs and accelerate time to market approval. Though safety and efficacy ultimately dictate the success of a new drug, other factors, for instance, manufacturing strategy and execution can largely impact the cost and timeline of the drug development

Based on the End-user Insights, the market is segmented into Pharmaceutical Companies, Biotech Companies and Others (Government, Research Institutes, Academic Institutes, etc.)

  • The pharmaceutical companies segment led the market and accounted for 69.4% in 2020. This can be attributed to the increasing investments in the pharmaceutical sector. There are roughly 7,000 different rare diseases that impact 350 million people worldwide, and more research is being done than ever before.
  • The biotech companies segment is anticipated to register a lucrative growth rate of 7.0% over the forecast period. The basic research is carried out both independently and in collaboration with researchers and others from various parts of the biomedical research ecosystem, such as disease foundations and patient organizations, venture capital, and pre-competitive consortia. It faces a lengthy development period that is unique to the field. 

IND CDMO Regional Outlook 

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

Key Companies Profile & Market Share Insights

Market players are implementing a range of strategic activities, such as new partnership agreements, collaborations, and mergers and acquisitions, with the objective of boosting their services and manufacturing services to gain a competitive advantage.

Some prominent players in the global investigational new drug (IND) CDMO market are:

  • Covance Inc.
  • Charles River Laboratories Inc.
  • Cambrex Corporation
  • IQVIA Holdings Inc.
  • Syneos Health
  • Lonza
  • Catalent
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.

 

Order a free sample PDF of the Investigational New Drug CDMO Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter

 

Comments

Post a Comment

Popular posts from this blog

Exploring the Rapid Growth of the Aerogel Market: Trends and Forecasts for 2024

  Aerogel Industry Overview   The global aerogel market size is expected to reach USD 3.49 billion by 2030, registering a CAGR of 17.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Aerogel has a wide application portfolio due to its unique qualities and ongoing research & development regarding its usage in new and advanced applications. Its properties including superior thermal resistance, lightweight, very low density, fire resistance, and excellent thermal insulation are likely to boost its demand across varied applications.   Aerogels can provide innovative and environment-friendly solutions for high-performance insulation and light-diffusing in a wide range of architectural daylighting applications. Major players offer advanced and innovative solutions for architectural applications. For instance, Cabot Corporation provides LUMIRA aerogel an innovative high-performance insulation for architectural daylighting. T...
Read more

Automotive Electronics Market size is expected to reach USD 468.17 billion by 2030

  Automotive Electronics Industry Overview The global automotive electronics market size was valued at USD 262.60 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2030. The increasing integration and implementation of advanced safety systems such as automatic emergency braking, airbags, parking assistance systems, and lane departure warning to decrease road accidents is expected to favor demand over the forecast period. Moreover, features such as emergency call systems, alcohol ignition interlocks, and accident data recorder systems are rapidly adopted to safeguard in-vehicle passengers and are expected to drive market growth over the forecast period.   Gather more insights about the market drivers, restrains and growth of the   Automotive Electronics Market   The increasing demand for electric vehicles is driving the demand for automotive electronics. Many people are switching from fuel ignited vehi...
Read more

Global Active Pharmaceutical Ingredients Market to Reach $359.45 Billion by 2030

  Active Pharmaceutical Ingredients (API) Market Growth & Trends The global  active pharmaceutical ingredients (API) market  is expected to reach a valuation of USD 359.45 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.85% from 2025 to 2030, according to a recent report by Grand View Research, Inc. This growth is primarily driven by the rapid expansion of the biopharmaceutical sector, continuous technological advancements in API manufacturing, and the rising aging population, which is leading to a greater demand for pharmaceuticals globally. One of the key growth drivers is the increasing investment in captive API production, where pharmaceutical companies focus on developing in-house manufacturing capabilities. By doing so, companies can reduce costs, ensure quality control, and mitigate the risk of contamination associated with outsourcing. Advances in artificial intelligence (AI) and protein synthesis technologies are further streamlining API...
Read more